Drug Profile
VAC 3S
Alternative Names: VAC-3SLatest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator Assistance Publique Hopitaux de Paris; INSERM; Universite Pierre et Marie Curie
- Developer InnaVirVax
- Class AIDS vaccines
- Mechanism of Action HIV envelope protein gp41 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II HIV-1 infections
Most Recent Events
- 08 Sep 2021 VAC 3S is still in phase II trials for HIV infections in France, Germany and Spain (IM)(InnaVirVax website, September 2021)
- 18 Oct 2018 VAC 3S is still in phase II trials for HIV infections (InnaVirVax website, October 2018)
- 04 Mar 2018 Efficacy and adverse events data from a phase II trial in HIV-1 infections presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI-2018)